Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a website bring BRCA testing to more people?

NCT ID NCT03351803

Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a digital health tool to help more people of Ashkenazi Jewish descent get tested for BRCA gene mutations, which increase cancer risk. Over 5,400 participants will use a web portal to learn about testing and decide whether to proceed. The goal is to see if this approach can make genetic testing a routine part of healthcare.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Digital health solution (web portal for genetic testing access)
What this could lead to
If successful, this could show that a digital approach can expand access to genetic testing for people at higher risk of BRCA-related cancers.
What could go wrong
This is an observational study focused on feasibility and access, not on treatment. It may not lead to direct health improvements, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

5,412 people

The number who actually took part.

Started

Nov 2017

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be invited to join the BFOR study through information provided to their PCPs by the testing laboratories, and media and community outreach. The study will also be promoted through search engines and by genetics providers who are aware of the study. Approach to the study will be entirely participant-initiated and controlled.

Ages

25 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Self-reported age ≥ 25 * Self identify as having at least one of their four grandparents as Ashkenazi Jewish * Has medical insurance * Able to understand and read the English-language * Zip code falls within the catchment areas of the phase of the study (e.g. New York City, Boston, Philadelphia, Los Angeles) accessible to a BFOR designated provider Exclusion Criteria: * Under age 25 * No Ashkenazi Jewish ancestry * Does not have insurance * Has previously had medical BRCA testing ordered by a health care provider

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA1 mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

BRCA1-related cancer predisposition BRCA2-related cancer predisposition

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1 mutation BRCA2 mutation

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Memorial Sloan - Kettering Cancer Center

    New York, New York, 10021, United States

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104-4283, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.